葡甘聚糖对2型糖尿病的疗效分析

Clinical Efficacy of Glucomannan in Type 2 Diabetic

目的观察葡甘聚糖(魔芋的主要成份)对2型糖尿病患者的血糖、血脂以及血压等的影响,同时观察葡甘聚糖用于2型糖尿病患者的耐受性。方法随机选择124例2型糖尿病患者在不改变原有治疗的情况下给予葡甘聚糖,并与随机同期选择124例2型糖尿病患者对照,12周后评价葡甘聚糖改善血糖、血脂以及血压等效果。结果治疗12周后,服用葡甘聚糖的糖尿病患者空腹血糖(FPG)水平下降(1.26±1.71)mmol/L(P<0.001)、餐后2小时血糖(2hPG)水平下降(2.15±2.18)mmol/L(P<0.001)、HbAlc水平下降(0.97±1.14)%(P<0.001)、总胆固醇(TC)水平下降(0.31±0.76)mmol/(P<0.001)、低密度脂蛋白(LDL-C)水平下降(0.32±0.85)mmol/l(P<0.01)。患者经过12周服用葡甘聚糖治疗,有1.6%的患者发生轻度胃肠道不良反应,未发生相关的严重不良事件。结论葡甘聚糖有显著改善2型糖尿病人高血糖的作用,能减少和延缓葡萄糖的吸收,并有助于改善糖尿病患者血脂代谢异常,有较好的安全性和耐受性。

Objective To investigate the effects of Glucomannan, glycemia control, and cardiovascular risk factors and to observe the safety and compliance of Glucornannan in type 2 diabetic patients. Methods They were randomized to receive Glucomannan 5g tid（n = 124） for 12 weeks and the effects of Glucomannan on reducing body weight, ameliorating blood glucose and lipids were evaluated.Results After 12 weeks,fasting plasma glucose of glucomannan - treated patients（ - 1.26 ± 1.71 ） mmol/L （ P 〈 0.001 ）, postprandial glucose （ - 2.15 ± 2.18） mmol/L（ P 〈 0.001 ）, HbAlc （ - 0.97 ± 1.14） % （ P 〈 0.001 ）, total cholesterol （ - 0.31 ± 0.76） mmol/L （ P 〈 0.001 ）, low - density lipoprotein cholesterol（ - 0.32 ± 0.85） mmol/L （ P 〈 0.01 ）. Both groups had Similar adverse - event profiles, except for mostly mildand transient gastrointestinal events in glucomannan - treated patients. There were no serious adverse events in both groups. Conclusion Glucomannan may improve glycemia and high triglyceride control in Type 2 diabetics. Glucomannan may delay the absorption of carbohydrates. It could be concluded that glucomannan was very useful in both prevention and treatment of glycemia.